← All candidates
9 insider filings on record.
28 filings on record.
QNCXQuince Therapeutics, Inc.
NasdaqGS · Healthcare · $30.05M
$29.55
+2.04% · Sep 11
9 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 1 sell
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what QNCX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$30.05M
Float
0.7M
67% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
4 more transactions on Pro →Context
Wall St
$77.20 avg target
+161.3% vs today · 5 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Coverage
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled TherapyInsider Monkey · 06-02Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failureClinical Trials Arena · 02-02Quince Therapeutics price target raised to $5 from $4 at D. Boral CapitalTipRanks · 12-16Reddit initiated, Caterpillar downgraded: Wall Street's top analyst callsThe Fly · 07-29
The file stays open
28 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice